Table 2.
Relapse rate and therapeutic regimens in group A and group B at V2*
| Group A | Group B | P † | |
|---|---|---|---|
| (n = 126) | (n = 124) | ||
| Patients with JIA relapse at V2 | 8 (6.3) | 21 (16.9) | 0.009‡ |
| Ongoing JIA treatment at V2 | |||
| NSAIDs | 6 (4.8) | 1 (0.8) | 0.120§ |
| Oral glucocorticoids | 0 | 0 | |
| Methotrexate | 45 (35.7) | 35 (28.2) | 0.204 |
| Sulfasalazine | 1 (0.8) | 2 (1.6) | 0.62§ |
| Biologic DMARDs | 53 (42.1) | 51 (41.1) | 0.881 |
| Etanercept | 28 (22.2) | 26 (21) | 0.810 |
| Adalimumab | 14 (11.1) | 10 (8.1) | 0.414 |
| Infliximab | 1 (0.8) | 3 (2.4) | 0.368§ |
| Tocilizumab | 7 (5.6) | 9 (7.3) | 0.582 |
| Canakinumab | 0 | 1 (0.8) | 0.496§ |
| Abatacept | 3 (2.4) | 2 (1.6) | 1.0§ |
| Off therapy | 36 (28.6) | 43 (34.7) | 0.299 |
| Therapeutic decision at V2 | |||
| Prescription of a new drug | 8 (6.3) | 19 (15.3) | 0.022‡ |
| Continuation of ongoing therapy, no./total no. (%) | 57/90 (63.3) | 50/81 (61.7) | 0.829 |
| Drug dosage increase, no./total no. (%) | 3/90 (3.3) | 4/81 (4.9) | 0.709§ |
| Drug tapering or 1 drug discontinuation, no./total no. (%)¶ | 25/90 (27.8) | 15/81 (18.5) | 0.153 |
| Therapy withdrawal, no./total no. (%) | 3/90 (3.3) | 4/81 (4.9) | 0.709§ |
| Out‐of‐school physical activity in the last month, no./total no. (%)# | 48/77 (62.3) | 4/110 (3.6) | <0.00001‡ |
*
Values are the number (%) unless indicated otherwise. V2 frame was from March 10, 2019 to June 30, 2019 in group A; and from March 10, 2020 to June 30, 2020 in group B. DMARDs = disease‐modifying antirheumatic drugs; JIA = juvenile idiopathic arthritis; NSAIDs = nonsteroidal antiinflammatory drugs.
†
By chi‐square test unless otherwise specified.
‡
Significant.
§
By Fisher's exact test.
¶
In case of combined medications regimens.
#
Data on sports activity outside school were available for 77 patients in group 1 and for 110 patients in group 2.